Navigation Links
Dendreon Reports First Quarter 2011 Financial Results

SEATTLE, May 2, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2011. Revenue for the quarter ended March 31, 2011 was $28.1 million compared to $21,000 for the quarter ended March 31, 2010.

The GAAP net loss for the quarter ended March 31, 2011 was $111.8 million, or $0.77 per share, compared to $125.7 million, or $0.96 per share for the quarter ended March 31, 2010 (which included a non-cash charge of $68 million loss from valuation of warrant liability). On a pro-forma basis, excluding non-cash expenses associated with depreciation and amortization, non-cash imputed interest expense, and non-cash deferred stock compensation, Dendreon’s net loss was approximately $85 million or $0.59 per share. Dendreon's total operating expenses for the quarter ended March 31, 2011 were $112.9 million compared to $57.6 million for the three months ended March 31, 2010.

As of March 31, 2011, Dendreon had approximately $779.0 million in cash, cash equivalents, and short-term and long-term investments compared to $277.3 million as of December 31, 2010.

Recent Highlights:

  • In addition to the $28.1 million in revenue in the first quarter, sales of PROVENGE® (sipuleucel-T) in April 2011 were approximately $15 million, reflecting increasing demand and increasing utilization of its newly approved capacity.  Dendreon continues to expect revenue this year of between $350-400 million with approximately half of that anticipated in the fourth quarter.
  • The number of accounts infusing PROVENGE as of March 31, 2011 increased from approximately 50 to approximately 135 and we are on track to meet our goal of 225 sites infusing PROVENGE by the end of Q2.
  • The U.S. Food and Drug Administration (FDA) approved the expanded New Jersey manufacturing facility.  The 36 additional workstations will come online in a staged approach.
  • Dendreon filed for FDA approval of the Los Angeles area manufacturing facility and has an action date of June 30, 2011. 
  • Dendreon filed for FDA approval of the Atlanta facility on April 28 and expects a decision in late August or early September.
  • The Centers for Medicare and Medicaid Services (CMS) issued a proposed decision memo supporting the on-label coverage of PROVENGE.
  • Dendreon selected a contract manufacturing organization in Europe and a location for a manufacturing facility outside Frankfurt, Germany.

  • "We are proud of our accomplishments as we continue to expand the launch of PROVENGE.  Our recent increased sales and marketing efforts have had an impact, and we will continue to build on this momentum as we bring additional capacity online throughout this year to make PROVENGE more broadly available," said Mitchell H. Gold, M.D., president and chief executive officer.

    Conference Call InformationDendreon will host a conference call on May 2, 2011 at 4:30 p.m. ET. To access the live call, dial 1-877-548-9590 (domestic) or +1-720-545-0037 (international); the conference ID number is 57436485. The call will also be audio webcast and will be available from the Company's website at under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-642-1687 or +1-706-645-9291 for international callers; the conference ID number is 57436485. The replay will be available from 7:30 p.m. ET on May 2 until 11:59 p.m. ET on May 9. In addition, the webcast will be archived for on-demand listening for 30 days at

    About DendreonDendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit

    This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. DENDREON CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months Ended
    March 31,20112010(unaudited)Revenue

    $28,061$21Cost of revenue

    18,338—Gross profit

    9,72321Operating expenses:Research and development

    17,60929,414Selling, general and administrative

    95,28928,218Total operating expenses

    112,89857,632Loss from operations

    (103,175)(57,611)Interest income

    400278Interest expense

    (8,993)(314)(Loss) gain from valuation of warrant liability

    —(68,083)Net loss

    ($111,768)($125,730)Basic and diluted net loss per share

    ($0.77)($0.96)Shares used in computation of basic anddiluted net loss per share

    145,494131,456March 31,December 31,20112010Balance Sheet Data:Cash and cash equivalents

    $555,297$132,995Short-term investments

    157,094121,796Long-term investments

    66,63022,505Trade accounts receivable

    16,86412,679Prepaid antigen costs


    38,87230,928Total  assets

    1,130,688603,953Convertible senior notes due 2016

    491,424—Convertible senior subordinated notes due 2014

    27,68527,685Total stockholders' equity

    526,451492,774DENDREON CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP NET LOSS (in thousands, except per share amounts)Three Months Ended
    March 31,20112010(unaudited)GAAP net loss

    ($111,768)($125,730)Non-GAAP adjustments:Depreciation and amortization expense

    7,4092,465Stock-based compensation expense

    14,6767,070Imputed interest related to the convertible
    senior notes due 2016

    4,300—Non-GAAP net loss

    ($85,383)($116,195)Non-GAAP net loss per share- basic and diluted

    ($0.59)($0.88)Shares used in computation of basic anddiluted net loss per share

    145,494131,456The above table provides certain non-GAAP financial measures that include adjustments to GAAP figures. Dendreon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Dendreon's financial performance and its prospects for the future. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of operational results and trends. We believe excluding these non-cash items provides important insight into our operational results, important for a company at our stage in development. In addition, these non-GAAP financial measures are among the indicators Dendreon management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP figures.

    SOURCE Dendreon Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Dendreon to Host Conference Call on May 2, 2011 to Announce First Quarter 2011 Financial Results
    2. Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
    3. Dendreon Announces Webcast Presentations at Four Upcoming Conferences
    4. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
    5. Dendreon to Host Conference Call on March 1st to Announce Fourth Quarter and Year-End Financial Results
    6. Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
    7. Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
    8. Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
    9. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
    10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
    11. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
    Post Your Comments:
    (Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
    (Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
    (Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
    (Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
    Breaking Biology Technology:
    (Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
    (Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
    (Date:10/27/2015)... , Oct. 27, 2015 In the ... issues of concern for various industry verticals such as ... due to the growing demand for secure & simplified ... various ,sectors, such as hacking of bank accounts, misuse ... electronic equipment such as PC,s, laptops, and smartphones are ...
    Breaking Biology News(10 mins):